News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Thermo Fisher set to benefit from demand for testing kits, vaccines

10/26/2021 | 01:11pm EDT
Visit to AstraZeneca/Thermo Fisher, former Novasep, COVID-19 vaccine plant in Belgium

    By Amruta Khandekar and Mrinalika Roy
    Oct 26 (Reuters) - Thermo Fisher Scientific Inc's
third-quarter profit is likely to get a boost from a rebound in
COVID-19 testing due to the highly contagious Delta variant and
sustained demand for vaccines against the coronavirus, Wall
Street analysts said.
    In July, when cases eased in the United States, the company
cut its annual sales forecast for COVID-19 tests by $900
million. But the demand has again picked up pace in recent
months amid a surge in Delta-led infections.
    The world's largest maker of scientific instruments, which
also supplies raw materials for COVID-19 vaccines and therapies,
may see some benefit from the United States authorizing booster
doses for some age-groups. 
    However, Thermo Fisher is unlikely to lift its testing
forecast, according to Atlantic Equities analyst James
Mainwaring, as it shifts its focus to its core business of
making scientific instruments used in pharmaceutical and
academic research.
    The business took a hit last year as the pandemic disrupted
research activities, but showed a strong recovery in the second
quarter.
    
    THE CONTEXT
    ** Thermo Fisher's COVID-19 response revenue, which consists
of supply for vaccines and therapies as well as testing kits,
helped cushion the hit to its mainstay business from COVID-19
curbs and beat profit expectations for the past few quarters.   
    ** Demand for test kits from employers in the United States
have surged in the past few months and has even resulted in a
supply crunch as the U.S. government mandated big employers to
inoculate their workers and test them every week.  
 
     ** Last week, rival Abbott Laboratories raised its
2021 profit forecast due to the recent uptick in testing demand.
However, Quest Diagnostics warned of a slowdown in
demand through the rest of the year as infections decline.

    
    THE FUNDAMENTALS
    ** Thermo Fisher is expected to report third-quarter revenue
of $8.39 billion on Oct. 27, according to the mean estimate from
15 analysts, based on Refinitiv data        

    ** Thermo Fisher reported overall second-quarter sales of
$9.27 billion. 

    
    
    WALL STREET SENTIMENT  
    ** The current average analyst rating on Thermo Fisher
shares is "buy", with eight analysts rating it "strong buy", 12
"buy" and two "hold"    
    ** Wall Street's median 12-month price target is $670    
    ** The company's shares have risen about 30.5% so far this
year

 QUARTER ENDING  EPS ESTIMATE   ACTUAL EPS($)  BEAT, MET,
                 ($)                           MISSED
 July. 3 2021    $5.44          $5.60          BEAT
 April. 3 2021   $6.65          $7.21          BEAT
 Dec. 31 2020    $6.56          $7.09          BEAT
 Sept. 26 2020   $4.31          $5.63          BEAT
 June. 27 2020   $3.42          $3.89          BEAT
 March. 28 2020  $2.79          $2.94          BEAT
 
    
 (Reporting by Amruta Khandekar and Mrinalika Roy in Bengaluru;
Editing by Arun Koyyur)
  

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.71% 113.24 Delayed Quote.-19.54%
S&P 500 0.01% 3901.36 Real-time Quote.-18.14%
THERMO FISHER SCIENTIFIC 0.80% 555.15 Delayed Quote.-17.46%
Latest news "Economy & Forex"
05:58pN.Korea reports 'positive trend' in COVID fight as fever cases dip
RE
05:34pWHO Says As Of 21 May, 92 Confirmed Cases And 28 Suspected Cases Of Monkeypox Have Been Reported To WHO From 12 Member States Not Endemic For The Virus
RE
05:34pWho says as of 21 may, 92 confirmed cases and 28 suspected cases…
RE
04:39pRussia intensifies push for Donbas, halts gas to Finland
RE
04:34pSiemens Energy launches $4.3 bln bid for remaining Siemens Gamesa stake
RE
04:32pNew York judge approves congressional map, throwing Democrats into disarray
RE
03:57pUKRAINE AND RUSSIA : What you need to know right now
RE
03:57pUKRAINE AND RUSSIA : What you need to know right now
RE
03:56pUkrainian negotiator rules out ceasefire or concessions to Russia
RE
03:22pUkraine's Zelenskiy talked to Italian PM, urged more Russia sanctions
RE
Latest news "Economy & Forex"